These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15270027)

  • 21. Is the drought over for pharming?
    Kaiser J
    Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
    [No Abstract]   [Full Text] [Related]  

  • 22. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 23. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 24. Will compounding exist in the 21st century?
    Lynn RC
    J Am Vet Med Assoc; 1994 Jul; 205(2):296-7. PubMed ID: 7928606
    [No Abstract]   [Full Text] [Related]  

  • 25. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug pipeline: Q311.
    Peng W
    Nat Biotechnol; 2011 Oct; 29(10):859. PubMed ID: 21997619
    [No Abstract]   [Full Text] [Related]  

  • 28. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FDA new drug approval process.
    Gifford RW
    Conn Med; 1980 May; 44(5):309-11. PubMed ID: 7379526
    [No Abstract]   [Full Text] [Related]  

  • 31. Is it time to rethink the expanded-access programs for HIV infection?
    Amorosa V; Tebas P
    J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revision of drug approval regulations proposed.
    FDA Drug Bull; 1982 Dec; 12(3):23-4. PubMed ID: 7166218
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 35. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 37. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 39. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.